IT'S NOT A SOCIAL DILEMMA – IT'S THE CALCULATED DESTRUCTION OF THE SOCIAL flux.md - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from flux.md Daily Mail and Mail on Sunday newspapers.
You can make a great recommendation algorithm, certainly better than YouTube s, if you use a different criteria for success. YouTube s criteria is to recommend whatever causes you to watch a lot of YouTube.
It could be that most people s goal in life is not to watch the maximum amount of YouTube.
One thing I ve wanted since I saw a prototype Joe Edelman made for Chrome, is after a video is played, prompt the user for a rating, and a reason for the rating. Joe had a taxonomy of human values for this, but it could also be a freeform tag based system.
Validating Game-Changing Approach to Live Event Ticketing
Investors for Series B include Chamath Palihapitiya’s Social Capital, music legend Quincy Jones and Rocketship VC, joining early shareholders Accomplice, Jackson Square Ventures and others
OFFICIAL PRESS RELEASE Shore Fire Media
Lyte, the technology platform that is transforming ticketing for live events, has announced $33 million in a Series B round, a combination of equity and debt, bringing its fundraising total to $48 million. The funding enables Lyte to continue its rapid growth beyond the nearly 300 top artist tours, festivals, venues and live events that use Lyte’s technology to power consumer flexibility, and confront the challenges created by the pandemic, in the event ticketing e-commerce experience.
5 Best Biotech Stocks to Invest In
5. Global Blood Therapeutics, Inc. (NASDAQ: GBT)
A clinical-stage biopharmaceutical company Global Blood Therapeutics, Inc. (NASDAQ: GBT) is the long-running investment of a billionaire hedge fund manager. The firm first initiated a stake in Global Blood Therapeutics in 2015. It is the fifth-largest stock holding of the Perceptive Advisors portfolio, accounting for 4.60% of the overall portfolio. The investment is valued at $319 million.
Shares of Global Blood Therapeutics underperformed this year compared to the broader market index. Lower than expected revenues from Oxbryta added to investors’ concerns. The company missed the third-quarter revenue estimate by $7.66 million. The market analysts believe share performance is likely to remain under pressure until Oxbryta sales reach the pre-Covid level.
10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund
Joseph Edelman is one of the most successful biotech hedge fund portfolio managers since he founded Perceptive Advisors in 1999, with the strategy of generating gains by investing in small and mid-cap biotechnology stocks. The assets under management of Edelman’s hedge fund soared from $6 million in 1999 to almost $6.85 billion in the last two decades.
Its flagship fund, Perceptive Life Sciences Fund, specializes in investing money in small- and mid-cap biotech companies. The fund reported losses in 2002, 2008 and 2018 when the broader biotech index fell at a high double-digit rate. Biotech stocks have a little correlation to the broader stock market because these stocks make moves on speculations and events such as trial results and FDA approval.